CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.
CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫效应细胞相关神经毒性综合征(ICANS)相关的认知障碍在接受CAR-T 细胞治疗的患者中很常见。本研究评估了时钟绘制任务(CDT)在检测接受CAR-T 治疗后的血液系统恶性肿瘤患者中ICANS的效用。数据收集自澳大利亚墨尔本The Alfred医院的CAR-T 患者。患者在住院期间接受了使用免疫效应细胞相关脑病(ICE)评分和CDT的频繁评估,CDT采用改良CLOX(CLOX-M)评定量表进行评分。
我们回顾性审查了2022年9月至2024年2月期间连续接受CAR-T 治疗患者的病历,以评估ICANS以及ICE评分和CLOX-M的变化。共对54例患者(39%为女性,64.36 13.25岁)的1208份时钟绘图在ICE评分1小时内进行了时间匹配。14例(26%)患者发生了ICANS。CLOX-M评分较基线的变化与ICE评分显著相关(= 0.34,p < 0.001)。受试者工作特征(ROC)分析表明,CLOX-M评分具有中等判别能力(曲线下面积[AUC] = 0.737)。CLOX-M评分下降2分或更多在检测ICANS方面具有高特异性(0.994),但敏感性较低(0.263)。CDT可用于补充ICE评分,以改善ICANS监测。
Immune effector cell-associated neurotoxicity syndrome (ICANS)-associated cognitive impairment is common in patients who receive chimeric antigen receptor T-cell (CAR-T) therapy.
This study evaluated the utility of the clock drawing task (CDT) in detecting ICANS in patients with haematological cancers following CAR-T therapy. Data were collected from CAR-T patients at The Alfred Hospital, Melbourne, Australia. Patients underwent frequent assessments using the immune effector cell-associated encephalopathy (ICE) score and the CDT, scored using a modified CLOX (CLOX-M) rating scale, during their admission.
We retrospectively reviewed the medical records of consecutive patients who received CAR-T therapy between September 2022 and February 2024 to assess for ICANS and changes in ICE score and CLOX-M. A total of 1208 clock drawings were time matched within an hour of an ICE score for 54 patients (39% female, 64. 36 13. 25 years). Fourteen (26%) patients developed ICANS. Change in CLOX-M scores from baseline and ICE scores was significantly correlated ( = 0.
34, p < 0. 001). Receiver operating characteristic (ROC) analysis demonstrated that the CLOX-M score has moderate discriminatory power (Area Under the Curve [AUC] = 0. 737). A decrease in CLOX-M score of 2 or more had high specificity (0. 994) but low sensitivity (0. 263) for detecting ICANS. The CDT can be used to complement the ICE score to improve ICANS monitoring.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。